Frontage Holdings Corporation (HKG:1521)

Market Cap	2.44B -16.4%
Revenue (ttm)	2.18B +10.0%
Net Income	83.29M +176.9%
EPS	0.04 +174.7%
Shares Out	2.03B
PE Ratio	29.42
Forward PE	12.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,000
Open	1.200
Previous Close	1.180
Day's Range	1.070 - 1.200
52-Week Range	0.680 - 1.500
Beta	0.22
Analysts	Strong Sell
Price Target	1.05 (-12.5%)
Earnings Date	Aug 28, 2026

About Frontage Holdings

Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,800
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1521

Financial Performance

In 2025, Frontage Holdings's revenue was $256.69 million, an increase of 0.70% compared to the previous year's $254.91 million. Earnings were $6.79 million, an increase of 758.79%.

Financial numbers in USD

Analyst Summary

According to 2 analysts, the average rating for 1521 stock is "Strong Sell." The 12-month stock price target is $1.05, which is a decrease of -12.50% from the latest price.

Price Target

$1.05

(-12.50% downside)

Analyst Consensus: Strong Sell

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error